Figure 3: AOA inhibits xenograft tumour growth of PIK3CA mutant CRCs but not PIK3CA WT CRCs.
From: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
(a) AOA inhibits growth of xenograft formed by HCT116 PIK3CA mutant clones but not PIK3CA WT clones. Three million cells were injected subcutaneously and bilaterally into athymic nude mice. Once tumours reached an average size of 100 mm3, 10 mg kg−1 of AOA was injected by intraperitoneal every day for 2 weeks. (b) AOA does not inhibit growth of xenograft tumours formed by GPT2 knockdown cells generated from a HCT116 PIK3CA mutant clone (Mut 1). Xenograft tumours of indicated cells were established and treated as described in a for 4 weeks. (c) AOA inhibits growth of xenograft tumours formed by the indicated four CRC cell lines harbouring PIK3CA mutations. (d) AOA does not inhibit growth of xenograft tumours formed by the indicated two CRC cell lines with WT PIK3CA. N=5 mice in each experimental group. Data are presented as mean±s.e.m. For HCT116 PIK3CA mutant clones, HCT116, DLD1, RKO and HT29, AOA treatment significantly inhibits xenograft tumour growth. P<0.001, two-way analysis of variance analysis.
